Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Shareholders held by OncoCyte Corporation (trading symbol: OCX) on June 17, 2020. The filing details the outcomes of shareholder votes regarding director elections, auditor ratification, and a corporate charter amendment.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Shareholder Actions
- Director Elections: Shareholders elected six directors (Ronald Andrews, Andrew Arno, Melinda Griffith, Alfred D. Kingsley, Andrew J. Last, and Cavan Redmond) to serve until the next annual meeting.
- Auditor Ratification: The appointment of OUM & Co. LLP as the independent registered public accountants for the fiscal year ending December 31, 2020, was ratified.
- Capital Structure Amendment: Shareholders approved an amendment to the Articles of Incorporation to increase the authorized number of common shares from 85,000,000 to 150,000,000.
Voting Results and Participation
As of the record date (May 12, 2020), there were 67,217,906 shares eligible to vote. Approximately 81.26% of the voting power (54,618,009 shares) was represented at the meeting.
| Matter | Votes For | Votes Against | Abstentions |
|---|---|---|---|
| Election of Directors (Aggregate) | 256,225,293 | 1,736,529 | N/A |
| Ratification of Accountants | 54,563,000 | 25,639 | 29,370 |
| Common Stock Amendment | 51,626,639 | 2,939,202 | 52,168 |
Note: There were 11,624,372 broker non-votes regarding the election of directors. There were no broker non-votes for the other matters.
Guidance, Risks, and Forward-Looking Statements
The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to factors outlined in the company's Form 10-K and Form 10-Q under "Risk Factors." The company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the impact of the increased authorized share count (150,000,000 shares) on potential future dilution.
- Review the full list of elected directors and their biographies in the company's proxy statement.
- Confirm the scope of the audit engagement with OUM & Co. LLP for the fiscal year ending December 31, 2020.
- Check subsequent filings for any issuance of shares under the newly authorized limit.